Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma
Open Access
- 16 February 2017
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (13) , 21539-21553
Abstract
Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanomaKeywords
This publication has 48 references indexed in Scilit:
- Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff OptimizationPLOS ONE, 2012
- On the armament and appearances of human myeloid-derived suppressor cellsClinical Immunology, 2012
- The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responsesNature Reviews Immunology, 2011
- CTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentationBMC Immunology, 2011
- Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other TumorsCancer Biotherapy and Radiopharmaceuticals, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cellsJournal of Experimental Medicine, 2009
- Myeloid-Derived Suppressor Cells Promote Cross-Tolerance in B-Cell Lymphoma by Expanding Regulatory T CellsCancer Research, 2008
- A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T CellsGastroenterology, 2008
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008